Phase 4
Completed N=5
Improving Sleep Quality in Heart Failure
Source: ClinicalTrials.gov NCT03307005 ↗Enrolled (actual)
5
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcomePrimary: Sleep Latency — -73.3; 21.9 minutes
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Poor sleep quality is common in patients with heart failure. The limited available evidence intimates that improving sleep quality in patients with heart failure may improve morbidity and quality of life in this patient population. However, there is a paucity of evidence assessing the use of effective pharmacologic therapies in heart failure. The nonbenzodiazepine, GABA receptor agonist, zolpidem, has been found to have considerable benefits over traditional benzodiazepines as a soporific medication. The investigators hypothesize that zolpidem will safely improve sleep quality in patients with heart failure.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Sleep Latency |
-73.3; 21.9 | — |
| PRIMARY Total Sleep Time |
67.8; -87.3 | — |
| PRIMARY Sleep Efficiency |
7.3; -5.5 | — |
Eligibility Criteria
Inclusion Criteria
- Age 21-79 years old
- HFrEF, EF ≤ 45% (by echocardiography)
- NYHA functional class I to III
- Able to give written consent
- On goal-directed medical therapy for HF, with stable dosing of HF medications for 2 weeks prior to enrollment
- No hospitalizations for HF within the past month
- Positive response to experiencing any of the following sleep-related symptoms at least once a week:
- Difficulty falling asleep
- Waking up during the night and having difficulty getting back to sleep
- Waking up too early in the morning and being unable to get back to sleep.
Exclusion Criteria
- Use of sedative-hypnotics, anxiolytic, or benzodiazepines within the previous 2 weeks
- Current treatment with other sedating medications such as opioids
- On therapy for pharmacological therapy for depression
- History of alcohol/drug dependence
- History of liver disease, HIV, or severe COPD
- On Thorazine
- Current use of ketoconazole
- Current use of tricyclic antidepressants
- Current use of macrolide antibiotics
- Current use of anticonvulsant medications
- Pregnancy. A urine pregnancy test will be performed to exclude pregnancy in potential subjects.
Data sourced from ClinicalTrials.gov (NCT03307005). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.